Skip to main content
Supplement ScienceSupplementScience

SAMe (S-Adenosyl Methionine) Side Effects & Safety

Evidence:Strong
·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

Safety Profile

Overall safety rating: Generally Safe

Potential Side Effects

  • Mild GI upset (nausea, diarrhea) — less frequent than with NSAIDs
  • Anxiety or insomnia at higher doses
  • Headache (uncommon)
  • May trigger mania in individuals with bipolar disorder — use with caution
  • Flatulence

Drug & Supplement Interactions

  • Antidepressants (SSRIs, MAOIs, tricyclics) — risk of serotonin syndrome; avoid combining or use under medical supervision
  • Levodopa — SAMe may reduce efficacy of levodopa in Parkinson disease
  • Medications metabolized by methylation — SAMe is a methyl donor and may alter drug metabolism

Maximum Dose

Do not exceed: 1,600mg daily has been used in depression trials without significant safety concerns; 1,200mg is typical for OA

Full SAMe (S-Adenosyl Methionine) Guide

References

  1. Meta-analysisSoeken KL, Lee WL, Bausell RB, et al. (2002). Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. Journal of Family Practice. PubMed
  2. RCTNajm WI, Reinsch S, Hoehler F, et al. (2004). S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. BMC Musculoskeletal Disorders. DOI PubMed
  3. RCTKim J, Lee EY, Koh EM, et al. (2009). Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis. Journal of Korean Medical Science. DOI PubMed
  4. ReviewHardy ML, Coulter I, Morton SC, et al. (2003). S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evidence Report/Technology Assessment (AHRQ). PubMed